Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Lung cancer has traditionally been classified by histology. However, a greater understanding of disease biology and the identification of oncogenic driver alterations has dramatically altered the therapeutic landscape. Consequently, the new classification paradigm of non-small-cell lung cancer is fu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2022-02, Vol.40 (6), p.611-625
Hauptverfasser:	Tan, Aaron C, Tan, Daniel S W
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biomarkers, Tumor - genetics Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Drug Resistance, Neoplasm - genetics Gene Rearrangement Genetic Predisposition to Disease Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Molecular Diagnostic Techniques Molecular Targeted Therapy Mutation Neoplasm Staging Oncogenes Phenotype Precision Medicine Predictive Value of Tests Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!